StreetInsider.com News Articles

Form 8-K NextCure, Inc. For: Jun 01

Mon, 01 Jun 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260601/26579694.html

Form 8-K NextCure, Inc. For: Jun 01

Mon, 01 Jun 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260601/26579694.html

NextCure reports positive SIM0505 trial data for gynecologic cancers

Mon, 01 Jun 2026 08:01:11 -0400

NextCure Inc. (NASDAQ: NXTC) and Simcere Zaiming Pharmaceutical Co. Ltd. announced positive Phase 1 dose escalation data for SIM0505, an investigational antibody drug conjugate targeting Cadherin-6, at the American Society for Clinical Oncology conference.

The study evaluated 59 heavily pre-treated cancer patients across the U.S. and China, with doses ranging from 1.6 mg/kg to 9.6 mg/kg. Within the therapeutic dose range of 4.8-8.0 mg/kg, the treatment showed an objective response rate of 55% in gynecologic cancers, 52.9% in ovarian cancer, and 66.7% in uterine serous carcinoma at 12 weeks by best response per RECIST 1.1 criteria.

The data cutoff was April 7,

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Mon, 01 Jun 2026 08:00:00 -0400

55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)
Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC
NextCure to host virtual Key Opinion Leader (KOL) Event June 2, 2026 at 8 AM ET

BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Mon, 01 Jun 2026 08:00:00 -0400

55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)
Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC
NextCure to host virtual Key Opinion Leader (KOL) Event June 2, 2026 at 8 AM ET

Form SCHEDULE 13G/A NextCure, Inc. Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Wed, 13 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260513/26486998.html

Form SCHEDULE 13G/A NextCure, Inc. Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Wed, 13 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260513/26486998.html

Lucid Capital Markets Starts NextCure Inc. (NXTC) at Buy

Mon, 11 May 2026 07:10:05 -0400

Lucid Capital Markets analyst Christopher Liu initiates coverage on NextCure Inc. (NASDAQ: NXTC) with a Buy rating and a price target of $25.00.

The analyst comments "NextCure (NXTC) is a clinical-stage biotechnology company focused on developing antibody- drug conjugates (ADCs) for cancer patients with limited treatment options, anchored by SIM0505 (a CDH6-directed ADC) and LNCB74 (a B7-H4-directed ADC). We note that the core focus of the company is on SIM0505 (CDH6 ADC), which was engineered for fast systemic clearance and an improved therapeutic window. The asset was in-licensed from Simcere

Lucid Capital Markets Starts NextCure Inc. (NXTC) at Buy

Mon, 11 May 2026 07:10:05 -0400

Lucid Capital Markets analyst Christopher Liu initiates coverage on NextCure Inc. (NASDAQ: NXTC) with a Buy rating and a price target of $25.00.

NextCure Inc. (NXTC) Misses Q1 EPS by 187c

Fri, 08 May 2026 05:42:54 -0400

NextCure Inc. (NASDAQ: NXTC) reported Q1 EPS of ($1.87).

For earnings history and earnings-related data on NextCure Inc. (NXTC) click here.

Form 10-Q NextCure, Inc. For: Mar 31

Thu, 07 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260507/26454136.html

Form 10-Q NextCure, Inc. For: Mar 31

Thu, 07 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260507/26454136.html

Form 8-K NextCure, Inc. For: May 07

Thu, 07 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260507/26453819.html

Form 8-K NextCure, Inc. For: May 07

Thu, 07 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260507/26453819.html

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers
SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026
LNCB74 Phase 1 dose escalation trial update planned in second half of 2026

BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported first quarter 2026 financial results.

"Our SIM0505 program reached critical milestones this quarter, headlined by the U.S. Food and Drug Administration (FDA)

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers
SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026
LNCB74 Phase 1 dose escalation trial update planned in second half of 2026

"Our SIM0505 program reached critical milestones this quarter, headlined by the U.S. Food and Drug Administration (FDA)

Form SCHEDULE 13G/A NextCure, Inc. Filed by: Simcere Zaiming, Inc.

Wed, 06 May 2026 21:27:00 -0400

si-local-file:///var/storage/secattach/20260506/26446090.html

Form SCHEDULE 13G/A NextCure, Inc. Filed by: Simcere Zaiming, Inc.

Wed, 06 May 2026 21:27:00 -0400

si-local-file:///var/storage/secattach/20260506/26446090.html

NextCure begins dose optimization study for ovarian cancer drug

Mon, 04 May 2026 07:05:57 -0400

NextCure Inc. (NASDAQ: NXTC) and Simcere Zaiming Pharmaceutical Co. announced the initiation of dose optimization for SIM0505, an investigational antibody drug conjugate targeting platinum-resistant ovarian cancer.

The dose optimization represents the next phase of a Phase 1 study evaluating SIM0505 in patients with advanced solid tumors. The drug combines an antibody targeting Cadherin-6 with a proprietary topoisomerase 1 inhibitor payload.

"Initiation of dose optimization highlights the promise of our novel CDH6-directed ADC and our focus on bringing SIM0505 to patients as quickly as possible," said Michael Richman, President and CEO of NextCure. The study aims to finalize dose selection and advance toward

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers